TRACON Pharmaceuticals, Inc. (TCON)
After hours:
| Previous close | 2.1100 |
| Open | 2.1200 |
| Bid | 1.9000 x 100 |
| Ask | 2.0300 x 100 |
| Day's range | 1.9300 - 2.1400 |
| 52-week range | 1.5900 - 36.8000 |
| Volume | |
| Avg. volume | 232,856 |
| Market cap | 4.459M |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2000 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 37.50 |
GlobeNewswireTRACON Pharmaceuticals Announces Reverse Stock Split
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that, following stockholder approval at the special meeting of stockholders held on September 6, 2023 of a proposal authorizing the board of directors of the Company (the
- GlobeNewswire
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024 SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced the independent data monitoring committee (IDMC), following a review of ongoing sa
Insider MonkeyTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript March 5, 2024 TRACON Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.03. TCON isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day ladies and gentlemen and […]
